1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Enforcement Roundup: Daniel Chapter One, Peanut Corp. Of America

Final chapter for Daniel Chapter One owner; prison sentence for head of salmonella-tainted peanut firm.

James Feijo, owner and operator of [Daniel Chapter One], a dietary supplement marketer that incurred FDA and the Federal Trade Commission enforcement, faces a potential prison sentence after pleading guilty to failing to pay more than $218,000 in employment taxes to the Internal Revenue Service. The Department of Justice on Sept. 15 said Feijo, 68, also pleaded guilty in federal court in Providence, R.I., to marketing and selling products making unapproved claims as cancer mitigation and treatment options. Separately, the Providence firm, which included a home-based church run by Feijo and his wife Trish Feijo, turned to the Supreme Court in 2011 after a lower court upheld FTC's order that the firm made misleading and unsubstantiated claims, including curing cancer, for its shark cartilage and herbal products. The high court declined to hear Feijo’s argument that FTC overstepped its legal authority with its enforcement action, which required the firm to notify customers it did not have sufficient evidence to support the claim Also see "Herbal Firm Denied Supreme Court Hearing Over Cancer Claim" - Pink Sheet, 30 May, 2011.. Feijo’s sentencing is scheduled for Jan. 12, DoJ said.

The former head of Peanut Corporation of America was sentenced to more than 27 years in prison for convictions on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.

More from North America

First Among Equals: US FDA CBER Director Prasad Gains Agency-Wide Authority

 
• By Bridget Silverman

As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.

BIO Notebook: MFN Pricing, Obesity R&D, US FDA’s Rare Disease Hub And Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.